An Epidural Letdown (4.4.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. **Correction: a Tweet from 3/18 podcast, had incorrect information. Late Breaking abstract from 2025 Amer. Acad. Dermatology (AAD) on the Phase 3 ICONIC-LEAD study showed J&J's oral IL-23 inhibitor (icotrokinra) was superior to PLACEBO (not deucravacitinib as reported) in skin clearance (65% vs 8%) & PASI90 (50% v 4%) at Wk 16 (NOT 15) in 684 moderate-to-severe plaque PsO pts https://buff.ly/dMbTbML

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Subscribe and Rate

Subscribe to the RheumNow podcast on your favorite podcast app to get automatic downloads of the latest content. Listen in the car, airplane, anywhere! We also reach more listeners through reviews from our users. Consider leaving a review!
 

 

×